Biocryst boosted by angioedema drug proof of concept
This article was originally published in Scrip
Executive Summary
Biocryst has announced positive proof-of-concept data for its prophylactic treatment for hereditary angioedema (HAE), BCX4161, sending its share price up by 11% to close at $9.99 on 27 May.